- Diabetic Chronic Dry Eye – Therapeutic
Principal Investigator(s) and Department
- Patricia McLaughlin, MS, DEd – Neural and Behavioral Sciences
- Joseph Sassani, MD, MHA – Ophthalmology
- Chronic Dry Eye in the Diabetic patient is prevalent in 20 million people in the US; 50 million worldwide.
- Most common course of treatment: OTC eye drops that need to be constantly applied or prescription medication that treats inflammation, but not the root cause of dry eyes and corneal sensitivity in the diabetic patient.
- Novel (patented) treatment (OCU-001).
- Significant animal data has proven efficacy and an FDA authorized Phase 1 study that demonstrated treatment was well-tolerated in humans.
- The OCU-001 formulation treats the source of diabetic dry eye, not just symptoms of inflammation, with a faster onset and reduced side effects to increase patient compliance.
For more information and to contact, please visit Ocunova’s website.